DJIA 16,466.15 114.77 0.70%
NASDAQ 4,779.75 29.77 0.63%
S&P 500 1,961.78 12.92 0.66%
market minute promo


company name or ticker

Is Biotech Finally In A Bubble?

Gilead: So Much More Than HCV

After Hours Most Active for Jun 2, 2015 : BBEP, QCOM, ACHN, OZM, NVAX, INFI, PDLI, TSM, HD, AA, GE,

After Hours Most Active for Jun 2, 2015 : BBEP, QCOM, ACHN, OZM, NVAX, INFI, PDLI, TSM, HD, AA, GE, WRI

Johnson & Johnson: Scary News Offers Opportunities To Increase Dividend Income For Retirement

Wait On The REITs - Cramer's Lightning Round (5/29/15)

'Mad Money' Lightning Round: Sell, Sell, Sell Achillion Pharmaceuticals

Gilead's Sustainable Competitive Advantage

Gilead Sciences' long-term growth is being doubted by the Street because of the uncertainty surrounding the hep C market going forward. The biotech's top notch CEO John Martin, however, should be reason enough for investors to believe that company's best days lie ahead. Here's why.

The Janssen-Achillion Deal Proves My Short Thesis

Seeking Alpha's Biotech Weekly: J&J-Achillion Vs. Gilead, MannKind's Marketing, And More

J&J (JNJ) to File for More than 10 New Products by 2019 - Analyst Blog

See More Articles...